(Q33636749)

28 July 2017

title

Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy (English)

1 reference

28 July 2017

1 reference

1

1 reference

28 July 2017

5

Zipursky RB

1 reference

28 July 2017

Cho R

2

1 reference

28 July 2017

Jones C

series ordinal

3

1 reference

28 July 2017

McKay G

series ordinal

4

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

28 July 2017

published in

Biological Psychiatry

1 reference

28 July 2017

volume

45

1 reference

28 July 2017

issue

9

1 reference

28 July 2017

page(s)

1217-1220

1 reference

Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

Response of psychotic depression subtypes to pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

A Method for the In Vivo Investigation of the Serotonergic 5-HT2Receptors in the Human Cerebral Cortex Using Positron Emission Tomography and18F-Labeled Setoperone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

A new framework for investigating antipsychotic action in humans: lessons from PET imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

Amoxapine - An Antidepressant With Some Neuroleptic Properties?: A Review of Its Chemistry, Animal Pharmacology and Toxicology, Human Pharmacology, and Clinical Efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

Risperidone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900204-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(98)00204-2

1 reference

28 July 2017

1 reference